ImClone Systems' BEC-2 vaccine
Executive Summary
Elicits immune responses in three of five advanced malignant melanoma patients injected with the anti-idiotype to the GD3 antigen found on cancerous cells. The Memorial Sloan-Kettering study was reported May 20 to the American Association for Cancer Research in San Diego. Phase I trials have been expanded to include patients with earlier stage disease and to investigate an additive effect from BCG adjuvant (Detox). ImClone plans to file an IND this year for BEC-2 in treatment of small cell lung cancer.